Sale,
Prospectus,
Broadridge Financial Solutions,
Security (finance),
Research,
Form S-3,
J. P. Morgan,
Form,
Patient,
Marketing,
BofA Securities,
Attention,
Telephone,
File RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share.
Key Points:
- RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share.
- RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions.
- RxSight filed a preliminary prospectus supplement and accompanying prospectus relating to the offering with the SEC on May 8, 2024.
- The offering may be made only by means of a prospectus supplement and accompanying prospectus.
Sale,
Prospectus,
Broadridge Financial Solutions,
Security (finance),
Research,
Form S-3,
J. P. Morgan,
Form,
Patient,
Marketing,
BofA Securities,
Attention,
Telephone,
File In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions.
Key Points:
- In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions.
- There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- An automatic shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on May 8, 2024, which became automatically effective upon filing.
- The proposed offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.
ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024.
Key Points:
- ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024.
- Revenue growth was driven by a 92% increase in LAL revenue and a 35% increase in LDD revenue, compared to the first quarter of 2023.
- Cash, cash equivalents and short-term investments as of March 31, 2024, were $125.4 million compared to $127.2 million at December 31, 2023.
- On Monday, May 6, 2024, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2024 financial results.
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024.
Key Points:
- ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024.
- The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applications are downloaded and installed.
- The call will also be available live and archived for one year at https://investors.rxsight.com/ .
Level 3,
Refractive surgery,
ASCRS,
BCEC,
Patient,
Level 2,
EDT,
Cataract,
Society,
Lens,
LAL,
Telescopic sight The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
Key Points:
- The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
- In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.
- At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including:
Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.
- A schedule of these presentations, which are not affiliated with the official ASCRS program, is available here and at the company’s booth throughout ASCRS.
Retrieved on:
Wednesday, March 27, 2024
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
Key Points:
- ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
- RxSight’s management is scheduled to participate in a fireside chat on Wednesday, April 10, 2024, at 12:45 p.m. Pacific Time / 3:45 p.m. Eastern Time.
- Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/ .
ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 34th Annual Oppenheimer Healthcare Conference.
Key Points:
- ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 34th Annual Oppenheimer Healthcare Conference.
- RxSight’s management is scheduled to participate in a fireside chat on Wednesday, March 13, 2024, at 8:20 a.m. Pacific Time / 11:20 a.m. Eastern Time.
- Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/ .
Retrieved on:
Wednesday, February 28, 2024
MCI Inc.,
Shareholder,
LDD,
Investment,
Growth,
Sale,
Annual general meeting,
LAL,
Patient,
Carolwood Pacific Railroad,
Video game Revenue growth was driven by a 52% increase in LDD revenue and a 98% increase in LAL revenue compared to the fourth quarter of 2022.
Key Points:
- Revenue growth was driven by a 52% increase in LDD revenue and a 98% increase in LAL revenue compared to the fourth quarter of 2022.
- Gross profit for the fourth quarter of 2023 was $17.7 million or 62% of revenue, an increase of $10.2 million or 138% compared to gross profit of $7.4 million or 46% of revenue for the fourth quarter of 2022.
- Total operating expenses for the fourth quarter of 2023 were $28.5 million, a 27% increase from $22.4 million in the fourth quarter of 2022, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL procedure volumes.
- On Wednesday, February 28, 2024, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter 2023 and full year 2023 financial results.
Retrieved on:
Wednesday, February 14, 2024
ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Wednesday, February 28, 2024.
Key Points:
- ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Wednesday, February 28, 2024.
- The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/ .
- While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applications are downloaded and installed.
ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.
Key Points:
- ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.
- Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2023, is expected to be $127.2 million.
- RxSight anticipates full-year 2024 revenue of $128.0 million to $135.0 million, reflecting growth of approximately 44% to 52% over 2023.
- Audited full-year 2023 and unaudited fourth quarter 2023 financial results are anticipated to be announced in February 2024.
